Despite good access to effective antibiotics, Streptococcus pneumoniae (pneumococci) is still a major cause of disease and death in both developing and developed countries. Pneumococci are the main cause of bacterial respiratory tract infections, such as pneumonia, middle ear infection, and sinusitis, in all age groups.
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics with significant case fatality rates.
Yellow fever (YF) is a mosquito-borne infection, distributed in west, central and east Africa and in South America. The disease can cause a wide spectrum of symptoms, from mild to fatal. In severe cases there may be spontaneous haemorrhage. Mortality of these clinical cases can be as high as 80%, on a par with Ebola, Marburg and other haemorrhagic viral infections.
This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 September-5 October 2019 and includes updates on Ebola virus disease, extensively drug-resistant Klebsiella pneumoniae, mass gathering monitoring (Japan, Rugby World Cup 2019), Middle East respiratory syndrome coronavirus, Plasmodium cynomolgi infection, poliomyelitis, West Nile virus, and yellow fever.